A comparative study of five centrally acting drugs on the pharmacological treatment of obesity
| Autor: | C M C dos Santos, M do Desterro de Figueiredo, Cesar Luiz Boguszewski, Henrique Lacerda Suplicy, D R Cunha, Rosana Bento Radominski |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
medicine.medical_specialty Centrally acting drugs Diet Reducing Endocrinology Diabetes and Metabolism MEDLINE Medicine (miscellaneous) Bioinformatics Body Mass Index Pharmacological treatment law.invention Randomized controlled trial law Fluoxetine Surveys and Questionnaires Internal medicine Weight Loss medicine Humans Obesity Prospective Studies Prospective cohort study Nutrition and Dietetics business.industry Amphetamines Follow up studies medicine.disease Mazindol Treatment Outcome Endocrinology Diethylpropion Female Anti-Obesity Agents business Body mass index Brazil Cyclobutanes Follow-Up Studies |
| Zdroj: | International Journal of Obesity. 38:1097-1103 |
| ISSN: | 1476-5497 0307-0565 |
| DOI: | 10.1038/ijo.2013.225 |
| Popis: | No long-term studies have compared centrally acting drugs for treating obesity.To compare the efficacy and safety of diethylpropion (DEP), fenproporex (FEN), mazindol (MZD), fluoxetine (FXT) and sibutramine (SIB) in promoting weight loss.A prospective, randomized, placebo (PCB)-controlled study conducted at a single academic institution.A total of 174 obese premenopausal women.Participants randomly received DEP 75 mg (n=28), FEN 25 mg (n=29), MZD 2 mg (n=29), SIB 15 mg (n=30), FXT 20 mg (n=29) or PCB (n=29) daily over 52 weeks. Diet and physical activity were encouraged.The primary endpoints were changes in body weight and the proportion of women who achieved at least 5% weight loss by week 52 in the intent-to-treat population. Other measurements included anthropometry, safety, metabolic and cardiovascular parameters.Weight loss was greater than PCB (-3.1±4.3 kg) with DEP (-10.0±6.4 kg; P0.001), SIB (-9.5±5.9 kg; P0.001), FEN (-7.8±6.9 kg; P0.01) and MZD (-7.4±4.9 kg; P0.01) but not with FXT (-2.5±4.1 kg). Ten (33.3%) women lost⩾5% of their initial weight with PCB, compared with 20 (71.4%; P0.001) with DEP, 20 (69%; P0.02) with FEN, 21 (72.4%; P0.01) with MZD, 22 (73.3%; P0.001) with SIB and 10 (35.5%) with FXT. Each medically treated group experienced more adverse events compared with PCB (P0.001). Compared with PCB, constipation was more prevalent with DEP, SIB and MZD (P0.01); anxiety was more prevalent with DEP (P=0.01); and irritability occurred more frequently with DEP and FEN (P=0.02). Significant improvements in the depression and anxiety scores, binge-eating episodes and quality of life correlated with weight loss.The centrally acting drugs DEP, FEN, MZD and SIB were more effective than PCB in promoting weight loss in obese premenopausal women, with a satisfactory benefit-risk profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|